For adjuvant treatment, might be very difficult to get coverage for Faslodex. Still could try Aromasin which is "approved" for adjuvant...and operaetes a little differently than the other AIs. I knwo my mom's onc back in '05 suggested that one might be easier to tolerate..but back then was not covered. Was approved later.
Seems worth trying. There is some suggestion that her2 therapies like Herceptin might push cancer cells towards being more active on the ER side...even if originally ER-. So if you already had some ER activity...
As an aside, have never heard a good thing about carbs and cancer..only
bad.
From a non-med standpoint, there is this on yoga:
http://www.ncbi.nlm.nih.gov/pubmed/22225932
Quote:
|
IMPLICATIONS FOR CANCER SURVIVORS: Results of this qualitative analysis indicate that interventions to support BCS with AIAA are warranted. Yoga appears to positively impact these side effects of hormonal therapies.
|
Managing the Side Effects of Aromatase Inhibitor Therapy
LINK
Quote:
|
The incidence of musculoskeletal issues appears to be highest in patients who are in transition into menopause, including patients who experience a loss of ovarian function secondary to chemotherapy.[15] Musculoskeletal issues appear to be most significant during the initial period that patients take AIs; they then improve over time. A retrospective analysis of the ATAC trial suggested that the presence of joint symptoms may be associated with a decreased risk for recurrence,[16] although such an association was not confirmed in an analysis of the MA.27 trial.[17] The management of musculoskeletal issues is challenging and poorly defined to date. Anti-inflammatory agents may be helpful in some patients, while many other patients can function without intervention, particularly as symptoms improve over time. There is anecdotal evidence to suggest that changing to an alternative AI may ameliorate symptoms, but as stated above, there is no evidence to suggest that one agent is less likely to cause musculoskeletal issues than another. In some patients, switching to tamoxifen, which has a lower incidence of musculoskeletal issues, may be necessary. There is some evidence to suggest that vitamin D may play some role in musculoskeletal complaints associated with AIs. In one study,[18] patients with normal or high vitamin D levels were less likely than those with low levels to report arthralgias when taking AIs. With vitamin D deficiency having been reported in more than two thirds of patients with early-stage breast cancer,[19] it would seem appropriate to check vitamin D levels and replace as necessary in patients in whom AI therapy is planned.
|